Yasuda Logistics Corporation (Headquarters: Tokyo, CEO: Nobuyuki Fujii, “Yasuda Logistics”) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that they have entered into a share purchase agreement concerning the transfer of all shares of Eisai’s wholly-owned subsidiary Eisai Distribution Co., Ltd. (Headquarters: Kanagawa, “Eisai Distribution”) to Yasuda Logistics. The date of the share transfer is scheduled to be March 31, 2023.


Eisai Distribution was established in April 1991 as a wholly-owned subsidiary of Eisai and is mainly responsible for logistics-related operations for Eisai Group products, contributing to their stable supply, and has a wealth of experience and know-how specialized in pharmaceutical logistics with a large track record in handling third-party products.


Yasuda Logistics has formulated “Long-term Vision for 2030” that designs what the company should be in 2030, and in order to realize the long-term vision, Yasuda has formulated a Middle-term Management Plan “YASDA Next Challenge 2024”, aiming to build a business structure toward further growth. Yasuda Logistic Group believes that the integration of Eisai Distribution’s prescription drug delivery network with the company’s experience in warehouse operations will improve its medical logistics services, which is an important pillar of its growth strategy, as well as expanding the number of warehouses and other facilities, leading to the realization of higher quality medical logstics services than ever.


Eisai has been working on creating pharmaceutical products and solutions to contribute to patients and the people in the daily living domain with the vision of “empowering people to realize their fullest life.” With the business environment surrounding pharmaceuticals logistics undergoing significant changes, through this agreement Eisai will pursue a more stable and efficient supply of Eisai Group products and concentrate on select business areas. Eisai expects that the synergistic effect of Eisai Distribution entering into the Yasuda Logistics Group will lead to the company’s sustainable growth and further expansion, as well as even greater contributions to the stable supply of pharmaceutical products in Japan.


Eisai Distribution will continue to be responsible for logistics-related operations for Eisai Group products after April 1, 2023. A certain period of time will be set as the transition period, during which Eisai will provide Yasuda Logistics with the necessary support for continuation of Eisai Distribution’s business.


As a result of this transaction, Eisai anticipates no changes to its consolidated financial forecast for the period ended March 31, 2023. Yasuda Logistics also anticipates no changes to its consolidated financial forecast for the period ended March 31, 2023.



Media Inquiries

[Notes to editors]

  1. 1.  About Eisai Distribution
Company name: Eisai Distribution Co., Ltd.
Location: 1-16-2 Iiyama Minami, Atsugi, Kanagawa
Representative: Masayuki Miyajima, Representative Director and President
Scope of business: Distribution (warehousing, storage, delivery) of pharmaceuticals, diagnostics, investigational drugs, pharmaceutical raw materials, foods and food additives, etc., pharmaceutical manufacturing (packaging, labeling, storage), wholesale distribution, warehousing, others
Capital: 60 million JPY
Date established: April 1, 1991
Number of employees: 65 (as of March 31, 2022)

2.  About Yasuda Logistics Corporation

Since the establishment in 1919, Yasuda Logistics Corporation has grown its logistics business in scope from the Tokyo metropolitan area to encompass the whole of Japan, and strive to better meet the needs of customers through providing logistics services. Yasuda also directed its energy towards the real estate business early on, continuing to work towards its dream of a wealthier society through the activities of both businesses, a dream that is coming to fruition today.

In order to build a business structure for further growth, the Yasuda Logistics Group has formulated “Long-term Vision for 2030” that designs what we should be in 2030, states that “Through a fusion of the world-renowned YASDA brand and innovative technology, our goal is to become a group that surpasses the expectations of all stakeholders.”

In addition, Yasuda has identified “expansion and improvement of logistics centers, and strengthening service provision systems in medical logistics business” as key strategy of its Middle-term Management Plan for FY 2022 to FY 2024 “YASDA Next Challenge 2024”, and has positioned strengthening pharmaceutical logistics business as a key pillar of Yasuda’s growth strategy.

For more information about Yasuda, please visit https://www.yasuda-soko.co.jp .


      1. 3.  About Eisai Co., Ltd.

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), Eisai aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, Eisai demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on Twitter @Eisai_SDGs.